The Durham VA is joining an 18-site clinical trial that will test GLP-1 medications as a treatment for alcohol use disorder among veterans. ABC11 reported that Durham recruitment begins August 17 as part of a Veterans Affairs study enrolling 622 participants nationwide. The trial will evaluate medicines already widely used for diabetes and weight management in a different clinical setting.
Researchers are testing whether the drugs reduce alcohol use and related harm rather than assuming that effects reported by individual patients are causal. The multi-site design allows investigators to compare outcomes across a larger and more varied veteran population than a single clinic could provide.
Investigators expect final results in roughly three years, reflecting recruitment, treatment, follow-up, and analysis time. Alcohol use disorder is a medical condition with behavioral and medication treatments, but no single approach works for every patient.
Randomized clinical trials use comparison groups and defined outcomes to estimate whether a treatment causes a benefit and to identify adverse effects. A trial announcement is not evidence that the medicine is effective for the new indication and does not change current prescribing approval on its own. Enrollment criteria, dosing, and the full protocol will determine which veterans can participate and what conclusions the study supports. The Durham site will begin screening participants after recruitment opens. Researchers will track retention, safety events, and alcohol-use outcomes throughout the study.
ABC11 reported that Durham recruitment begins August 17 as part of a Veterans Affairs study enrolling 622 participants nationwide. The trial will evaluate medicines already widely used for diabetes and weight management in a different clinical setting. Researchers are testing whether the drugs reduce alcohol use and related harm rather than assuming that effects reported by individual patients are causal. The multi-site design allows investigators to compare outcomes across a larger and more varied veteran population than a single clinic could provide. Investigators expect final results in roughly three years, reflecting recruitment, treatment, follow-up, and analysis time. Alcohol use disorder is a medical condition with behavioral and medication treatments, but no single approach works for every patient. Randomized clinical trials use comparison groups and defined outcomes to estimate whether a treatment causes a benefit and to identify adverse effects. A trial announcement is not evidence that the medicine is effective for the new indication and does not change current prescribing approval on its own. Enrollment criteria, dosing, and the full protocol will determine which veterans can participate and what conclusions the study supports.